Researcher profile

Edward Santos

Edward Santos contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 13 - Baseline
2works
0followers
4topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2022arXiv

Preserving the validity of the Two-Higgs Doublet Model up to the Planck scale

We examine the constraints on the two Higgs doublet model (2HDM) due to the stability of the scalar potential and absence of Landau poles at energy scales below the Planck scale. We employ the most general 2HDM that incorporates an approximately Standard Model (SM) Higgs boson with a flavor aligned Yukawa sector to eliminate potential tree-level Higgs-mediated flavor changing neutral currents. Using basis independent techniques, we exhibit robust regimes of the 2HDM parameter space with a 125 GeV SM-like Higgs boson that is stable and perturbative up to the Planck scale. Implications for the heavy scalar spectrum are exhibited.

preprint2021arXiv

Deep Learning for Distinguishing Normal versus Abnormal Chest Radiographs and Generalization to Unseen Diseases

Chest radiography (CXR) is the most widely-used thoracic clinical imaging modality and is crucial for guiding the management of cardiothoracic conditions. The detection of specific CXR findings has been the main focus of several artificial intelligence (AI) systems. However, the wide range of possible CXR abnormalities makes it impractical to build specific systems to detect every possible condition. In this work, we developed and evaluated an AI system to classify CXRs as normal or abnormal. For development, we used a de-identified dataset of 248,445 patients from a multi-city hospital network in India. To assess generalizability, we evaluated our system using 6 international datasets from India, China, and the United States. Of these datasets, 4 focused on diseases that the AI was not trained to detect: 2 datasets with tuberculosis and 2 datasets with coronavirus disease 2019. Our results suggest that the AI system generalizes to new patient populations and abnormalities. In a simulated workflow where the AI system prioritized abnormal cases, the turnaround time for abnormal cases reduced by 7-28%. These results represent an important step towards evaluating whether AI can be safely used to flag cases in a general setting where previously unseen abnormalities exist.